Young G - Search Results

1

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab.

Carcao M, Escuriola-Ettingshausen C, Santagostino E, Oldenburg J, Liesner R, Nolan B, Bátorová A, Haya S, Young G; Future of Immunotolerance Treatment Group. Carcao M, et al. Among authors: young g. Haemophilia. 2019 Jul;25(4):676-684. doi: 10.1111/hae.13762. Epub 2019 Apr 29. Haemophilia. 2019. PMID: 31033112 Free PMC article.

2

Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors.

Schneiderman J, Nugent DJ, Young G. Schneiderman J, et al. Among authors: young g. Haemophilia. 2004 Jul;10(4):347-51. doi: 10.1111/j.1365-2516.2004.00912.x. Haemophilia. 2004. PMID: 15230948

3

Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors.

Young G, McDaniel M, Nugent DJ. Young G, et al. Haemophilia. 2005 May;11(3):203-7. doi: 10.1111/j.1365-2516.2005.01096.x. Haemophilia. 2005. PMID: 15876264

4

Rituximab treatment of mild haemophilia A with inhibitors: a proposed treatment protocol.

Dunkley S, Kershaw G, Young G, Warburton P, Lindeman R, Matthews S, Rennisson F. Dunkley S, et al. Among authors: young g. Haemophilia. 2006 Nov;12(6):663-7. doi: 10.1111/j.1365-2516.2006.01351.x. Haemophilia. 2006. PMID: 17083518

5

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.

Teitel J, Berntorp E, Collins P, D'Oiron R, Ewenstein B, Gomperts E, Goudemand J, Gringeri A, Key N, Leissinger C, Monahan P, Young G. Teitel J, et al. Among authors: young g. Haemophilia. 2007 May;13(3):256-63. doi: 10.1111/j.1365-2516.2007.01449.x. Haemophilia. 2007. PMID: 17498074

6

Comparison of kaolin and tissue factor activated thromboelastography in haemophilia.

Young G, Zhang R, Miller R, Yassin D, Nugent DJ. Young G, et al. Haemophilia. 2010 May;16(3):518-24. doi: 10.1111/j.1365-2516.2009.02165.x. Epub 2009 Dec 17. Haemophilia. 2010. PMID: 20028419

7

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.

Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, Young G, Bidlingmaier C, Brandao LR, Ettingshausen CE, Gringeri A, Kenet G, Knöfler R, Kreuz W, Kurnik K, Manner D, Santagostino E, Mannucci PM, Nowak-Göttl U. Iorio A, et al. Among authors: young g. J Thromb Haemost. 2010 Jun;8(6):1256-65. doi: 10.1111/j.1538-7836.2010.03823.x. Epub 2010 Mar 17. J Thromb Haemost. 2010. PMID: 20345722 Free article. Review.

8

When should prophylaxis therapy in inhibitor patients be considered?

Young G, Auerswald G, Jimenez-Yuste V, Konkle BA, Lambert T, Morfini M, Santagostino E, Blanchette V. Young G, et al. Haemophilia. 2011 Sep;17(5):e849-57. doi: 10.1111/j.1365-2516.2011.02494.x. Epub 2011 Mar 21. Haemophilia. 2011. PMID: 21418444 Review.

9

Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008).

Young G, Cooper DL, Gut RZ; HTRS Investigators. Young G, et al. Haemophilia. 2012 Nov;18(6):990-6. doi: 10.1111/j.1365-2516.2012.02864.x. Epub 2012 May 28. Haemophilia. 2012. PMID: 22631073

10

From boy to man: recommendations for the transition process in haemophilia.

Young G. Young G. Haemophilia. 2012 Jul;18 Suppl 5:27-32. doi: 10.1111/j.1365-2516.2012.02893.x. Haemophilia. 2012. PMID: 22757681

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,182 results

Search Page

Filters